CLINICAL & PIPELINE·Drug Approval
Ionis Pharmaceuticals Completes Phase 2a Clinical Trial for IONIS-FB-LRx in Primary IgA Nephropathy
Ionis Pharmaceuticals, Inc. has completed its Phase 2a clinical study (NCT04014335) of IONIS-FB-LRx for primary IgA Nephropathy. This antisense inhibitor targets complement factor B, a crucial pathway in kidney disease. The trial, enrolling 23 participants across multiple countries, evaluated effectiveness and safety, marking a key milestone in the development of this novel therapeutic for a significant unmet medical need.
90-Day Activity